Video

The Platform Problem: Why Legacy mAb Platforms Might Be A Liability

Source: 3M Biopharmaceutical Purification

Years ago, the head office invested mightily in an antibody manufacturing platform. Today, the complexity of the molecule and the intricacies of their manufacturing processes are robbing the platform of its value. What to do? EQRx Sr. Director of Manufacturing Sciences & Technology Avril Vermunt and AltruBio Chief Technical Officer Gene Lee tackle the tough question in this segment of the Bioprocess Online Live Event Overcoming Platform Inefficiencies In mAb Manufacturing.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

3M Biopharmaceutical Purification